{
  "folder": "IC-223",
  "content": "{{knowledge objective\n|Identifiant=OIC-223-09-A\n|Item_parent=Dyslipidaemia\n|Item_parent_short=Dyslipidemia\n|Rank=A\n|Title=Know the principles of dyslipidemia treatment (see item 330)\n|Description=None\n|Rubric=Management\n|Contributors=Laurence Duvillard, Bruno Verg\u00e8s, Benjamin Bouillet, Laurence Amar, Christian Boissier, Tristan Mirault, Claire Le Hello\n|Order=9}}\n\n\n==Treatment of hypercholesterolaemia== (in French)\n\n*Decision on treatment based on LDL-cholesterol levels in relation to the patient's cardiovascular risk profile: [[Risk factor, aetiological factor, prognostic factor, health determinants, exposure factor 2C-020-DE-A04]].\n*Statin treatment as first-line treatment.\n*If target not achieved on statin, combine with ezetimibe or even cholestyramine.\n*In severe forms, PCSK9 inhibitors may be used.\n\n===In patients aged \u2265 40 years without diabetes, familial hypercholesterolaemia, renal insufficiency or known cardiovascular disease:===\n\n*in cases of ''very high cardiovascular risk'', an ''LDL-cholesterol target < 1.4 mmol/L'' (i.e. 0.55 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n*in cases of ''high cardiovascular risk'', an ''LDL-cholesterol target < 1.8 mmol/L'' (i.e. 0.70 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n*in cases of ''moderate'' or ''low'' cardiovascular risk, an ''LDL-cholesterol target < 2.6 mmol/L'' (i.e. 1.00 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337). In cases of ''low cardiovascular risk'', the recommendations of the ''NSFA-SFD-SFE 2014'' set a value ''< 4.9 mmol/L'' (i.e. 1.90 g/L).\n\n===In people with diabetes:===\n\n*in cases of ''very high cardiovascular risk'', an ''LDL-cholesterol target < 1.4 mmol/L'' (i.e. 0.55 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n*in cases of ''high cardiovascular risk'', an ''LDL-cholesterol target < 1.8 mmol/L'' (i.e. 0.70 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n*in cases of ''moderate'' ''or low'' cardiovascular risk, an ''LDL-cholesterol target < 2.6 mmol/L'' (i.e. 1.00 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n\n===In patients with renal failure:===\n\n*in cases of ''very high cardiovascular risk'', an ''LDL-cholesterol target < 1.4 mmol/L'' (i.e. 0.55 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n*in cases of ''high cardiovascular risk'', an ''LDL-cholesterol target < 1.8 mmol/L'' (i.e. 0.70 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n*in cases of ''moderate or low cardiovascular risk'', an ''LDL-cholesterol target < 2.6 mmol/L'' (i.e. 1.00 g/L) is recommended (European consensus ESC 2021: European Heart Journal 2021;42:3227-3337)\n\n===In patients with familial hypercholesterolaemia:===\n\n*LDL-cholesterol target < 3.5 mmol/L (i.e. 1.35 g/L) in children (often 4 mmol/L (i.e. 1.6 g/L) until puberty),\n*''LDL-cholesterol target < 2.6 mmol/L'' (i.e. 1.00 g/L) in adults treated early without additional cardiovascular risk factors (some practitioners target 3.3 mmol/L (i.e. 1.3 g/L), the median concentration for the French population),\n*LDL-cholesterol target < 1.8 mmol/L (i.e. 0.70 g/L) for adults treated late with additional cardiovascular risk factors,\n*LDL-cholesterol target < 1.4 mmol/L'' (i.e. 0.55 g/L) in secondary prevention (limited level of evidence in heterozygous familial hypercholesterolaemia).\n\n==Treatment of hypertriglyceridemia=\nIsolated hypertriglyceridaemia:\n\n*Initially, dietary measures should be preferred.\n*If triglycerides > 5.6 mmol/L (i.e. 5g/L): treatment with fibrates or fibrates + omega 3, if necessary.\n\n==Treatment of mixed hyperlipidaemia=\nPriority objective= normalisation of LDL-cholesterol (according to the rules above)\n\nOnce the LDL-cholesterol target has been reached, it may be suggested that fibrate treatment (preferably fenofibrate; never gemfibrozil) be added in high-risk cardiovascular patients with triglyceride levels \u2265 5.2 mmol/L (i.e. 2.0 g/L)= and low HDL-cholesterol.\n\n==Surveillance==\n\n===Effectiveness of treatment===\nLipid profile 2 to 3 months after initiation of treatment to check that lipid targets are being met, then annually.\n\n===Clinical tolerance===\nSearch for myalgias\n\n===Biological tolerance===\nMeasurement of transaminases, before and within 3 months of starting treatment,\n\nCPK measurement only if myalgia",
  "question": {
    "question": "In patients with familial hypercholesterolaemia, what is the recommended LDL-cholesterol target for adults treated early without additional cardiovascular risk factors?",
    "option_a": "LDL-cholesterol target < 1.8 mmol/L (i.e. 0.70 g/L)",
    "option_b": "LDL-cholesterol target < 2.6 mmol/L (i.e. 1.00 g/L)",
    "option_c": "LDL-cholesterol target < 3.5 mmol/L (i.e. 1.35 g/L)",
    "option_d": "LDL-cholesterol target < 4.9 mmol/L (i.e. 1.90 g/L)",
    "correct_option": "LDL-cholesterol target < 2.6 mmol/L (i.e. 1.00 g/L)"
  }
}